ESCRS - Ozurdex launched in China for RVO ;

Ozurdex launched in China for RVO

Colin Kerr

Published: Tuesday, May 1, 2018

Allergan has announced the launch of Ozurdex (dexamethasone intravitreal implant 0.7mg) in China for the treatment of adult patients with macular oedema secondary to retinal vein occlusion (RVO). Ozurdex is the first approved intravitreal injection for RVO in China and is licensed for the treatment of macular oedema following BRVO and CRVO. “Providing millions of RVO patients access to Ozurdex is a significant step towards preventing blindness and meeting a critical unmet need in China,” said Marc Princen, Allergan International President. http://www.allergan.com/

Latest Articles

From Lab to Life: Corneal Repair Goes Cellular

Long-awaited cellular therapies for corneal endothelial disease enter the clinic.

Balancing Innovation and Safety

Ensuring access to advanced cell therapies amid regulatory overhaul.

With Eyes on Its Future, ESCRS Celebrates Its Past

Winter Meeting offers opportunities to experiment with new concepts and formats.

Best of ESCRS Winter Meeting 2024

Following the New Generation

EDOF IOLs an option for eyes with mild comorbidities, showing potential in mini-monovision strategies.

Refocus on Multifocals

Trifocal IOLs continue to improve as consensus grows regarding indications and contraindications.

Common Myths in Presbyopia Correction

Patient education key to satisfaction with refractive IOLs.

Reversible Multifocality

Two-lens combination offers low-risk spectacle independence for cataract patients and presbyopes.

Managing a Cataract Surgery Refractive Miss

Weighing the pros and cons of options for intraocular intervention.

Unleashing OCT’s Full Potential

Performance of newest tool for corneal evaluation meets or beats older standard technologies.

;